Poster: Safety and monitoring in patients receiving casirivimab and imdevimab for COVID-19

Overview

This collection of posters are supportive tools based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for  healthcare workers who are prescribing, preparing, and administering the neutralizing monoclonal antibody casirivimab and imdevimab in patients with non-severe, severe, and critical COVID-19 infection. 

They provide information on the following for casirivimab and imdevimab:

1. Patient selection
2. Dosage consideration based on disease severity
3. Preparation and dilution instructions for intravenous formulation
4. Preparation and administration instructions for subcutaneous formulation
5. Safety and monitoring considerations